Results 121 to 130 of about 47,659 (253)

Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential. [PDF]

Bone Rep
Ursachi VC, Horak J, Fafilek B.
europepmc   +1 more source

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19? [PDF]

Int J Mol Sci, 2020
Giorgi M, Cardarelli S, Ragusa F, Saliola M, Biagioni S, Poiana G, Naro F, Massimi M.   +7 more
europepmc   +1 more source

Adenosine—A Regulator of Human Testicular Peritubular Cells

Andrology, EarlyView.
ABSTRACT Background Extracellular purines, in particular ATP and adenosine, are regulators of physiological and pathophysiological processes throughout the human body. Roles in the human testis are emerging and include actions on peritubular cells, which form the wall of seminiferous tubules.
Lina Scholz, Annika Liebich, Youli Stepanov, Jan B. Stöckl, Mirko Peitzsch, Michaela Schneider, Julia Schneider, Nicole Kreitmair, Matthias Trottmann, Frank‐Michael Köhn, Jovica Ninkovic, Thomas Fröhlich, Artur Mayerhofer   +12 more
wiley   +1 more source

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors. [PDF]

Front Pharmacol, 2020
Joskova M, Mokry J, Franova S.
europepmc   +1 more source

Temporal Trends in Intracavernosal Injection Therapy and Penile Prosthesis Implantation in the Era of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction in Australia

ANZ Journal of Surgery, EarlyView.
ABSTRACT Introduction Phosphodiesterase‐5 inhibitors (PDE5‐Is) transformed erectile dysfunction (ED) management as first‐line therapy; nonetheless, many patients require second‐ and third‐line options due to inadequate response, side effects, or contraindications.
Nicholas Gillman, Eric Chung
wiley   +1 more source

Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review. [PDF]

Transl Androl Urol
Bakhsh A, Rajih E, Barayan GA, Garah E, Khan I, Alrehaili Z, Alhejaili S, Almuways M, Aloufi T, Alnazawi H, Alharbi A, Farghal D, Badawi A.   +12 more
europepmc   +1 more source

Function drives 1‐year decision regret in radical prostatectomy: a multicentre prospective study

BJU International, EarlyView.
Objectives To identify contemporary drivers of postoperative decision regret 1 year after radical prostatectomy (RP). Patients and Methods In this prospective, multicentre study, patients undergoing robot‐assisted RP (RARP) or retropubic open RP (ORP) for localised prostate cancer at seven centres in Germany and Austria (2022–2024) completed ...
Christopher Hirtsiefer, Emma Kümmel, Anna Vogelgesang, Fabian Falkenbach, Mona Kafka, Annemarie Uhlig, Tim Nestler, Cem Aksoy, Iva Simunovic, Johannes Huber, Isabel Heidegger, Markus Graefen, Marianne Leitsmann, Christian Thomas, Martin Baunacke   +14 more
wiley   +1 more source

Phosphodiesterase Inhibitor [PDF]

, 2020
openaire   +1 more source

The Emerging Role of Phosphodiesterase Inhibitors in Fragile X Syndrome and Autism Spectrum Disorder. [PDF]

Pharmaceuticals (Basel)
Thomas SD, Mohammed HA, Hamad MIK, Oz M, Statsenko Y, Sadek B.   +5 more
europepmc   +1 more source

Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. [PDF]

Mol Oncol, 2020
Longo J, Pandyra AA, Stachura P, Minden MD, Schimmer AD, Penn LZ.   +5 more
europepmc   +1 more source